Clinical Trials Logo

Advanced Solid Tumors clinical trials

View clinical trials related to Advanced Solid Tumors.

Filter by:

NCT ID: NCT06242691 Recruiting - Clinical trials for Advanced Solid Tumors

Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors

Start date: February 28, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of MK-1200 monotherapy in participants with advanced/metastatic gastric/gastroesophageal junction (GEJ) cancer, esophageal cancer, biliary tract cancer, and pancreatic ductal adenocarcinoma who have received, or been intolerant to, all treatments known to confer clinical benefit. Part 1 of the study will be a dose escalation to determine the maximum tolerated dose (MTD). Part 2 will evaluate safety and efficacy of MK-1200 at 2 different doses

NCT ID: NCT06239155 Recruiting - Clinical trials for Hepatocellular Carcinoma

A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors

Start date: September 3, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

An open-label, Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of AST-3424 administered as a single agent

NCT ID: NCT06235983 Recruiting - Clinical trials for Advanced Solid Tumors

A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors

Start date: February 29, 2024
Phase: Phase 1
Study type: Interventional

This is an open-label, single-arm, multicenter, Phase 1 study of LY3537982 as monotherapy in Chinese participants with KRAS G12C-mutant advanced solid tumors. The main purpose of this study is to determine how much of LY3537982 gets into the bloodstream and how long it takes the body to eliminate it in Chinese participants. The safety, tolerability and preliminary efficacy of LY3537982 will also be evaluated. Approximately 12 patients will be enrolled in this study.

NCT ID: NCT06214143 Recruiting - Clinical trials for Advanced Solid Tumors

A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors

Start date: January 11, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical study evaluated the efficacy and safety of T3011 in combination with PD-1/PD-L1 inhibitors in subjects with advanced solid tumors

NCT ID: NCT06209580 Recruiting - Clinical trials for Advanced Solid Tumors

AMT-253 in Patients With Advanced Solid Tumours

Start date: January 31, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a non-randomized, open-label, multicenter Phase I/II study of AMT-253 in patients with Unresectable or Metastatic Malignant Melanoma and other Advanced Solid Tumors. This study include phase I dose escalation and phase II dose expansion.

NCT ID: NCT06208410 Recruiting - Clinical trials for Advanced Solid Tumors

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

Start date: January 11, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This study is an open-label, multicenter, Phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JS105 in combination with other anti-tumor therapies in patients with advanced solid tumors. Patients will be enrolled in two stages: a dose-escalation stage and a dose-expansion stage.

NCT ID: NCT06188208 Recruiting - Clinical trials for Advanced Solid Tumors

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors

Start date: January 5, 2024
Phase: Phase 1
Study type: Interventional

A FIH study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VVD-130850, as single agent and in combination with checkpoint inhibition, in participants with advanced solid and hematologic tumors.

NCT ID: NCT06178614 Recruiting - Clinical trials for Advanced Solid Tumors

A Study of JNJ-87890387 for Advanced Solid Tumors

Start date: December 14, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).

NCT ID: NCT06167317 Recruiting - Clinical trials for Advanced Solid Tumors

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

Start date: January 9, 2024
Phase: Phase 1
Study type: Interventional

The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-0201 when given alone or in combination with sacituzumab govitecan (SG) in participants with advanced solid tumors. The primary objectives of this study are to: - To assess the safety and tolerability of GS-0201 as monotherapy and in combination with SG in participants with selected advanced solid tumors - To identify the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of GS-0201 as monotherapy and the MTD and/or the RP2D and dosing schedule of GS-0201 in combination with SG in participants with selected advanced solid tumors

NCT ID: NCT06131398 Recruiting - Clinical trials for Advanced Solid Tumors

A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

Start date: March 7, 2024
Phase: Phase 1
Study type: Interventional

The primary objectives of this study are to: - Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors - Determine the recommended phase 2 dose and the maximum tolerated dose for AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors.